Exercise during curative chemotherapy for breast cancer has proven benefits. It helps reduce fatigue, preserve muscle strength, improve fitness, and enhance overall quality of life. Staying physically active…
With a wave of FDA approvals and promising clinical trials, treatment options for metastatic breast cancer are expanding fast. Amy Tiersten, MD, highlights the power of immunotherapies—especially checkpoint…
Jae H. Park, MD, hematologic oncologist and attending physician at the Leukemia Service and Cellular Therapeutics Center of Memorial Sloan Kettering Cancer Center, discusses the future of chimeric…
Craig L. Slingluff Jr, MD, director of surgical oncology at the Emily Couric Clinical Cancer Center at the University of Virginia, discusses the use of seviprotimut-L vaccine against…
Yousef Zakharia, MD, clinical associate professor of internal medicine at the University of Iowa Holden Comprehensive Cancer Center, discusses completing a recent phase 1 trial studying seleno-L-methionine (SLM)…
Elizabeth R. Plimack, MD, MS, chief of the Division of Genitourinary Medical Oncology, director of Genitourinary Clinical Research, and professor in the Department of Hematology/Oncology at Fox Chase…
Bradley McGregor, MD, clinical director at Lank Center for Genitourinary Oncology, senior physician at Dana-Farber Cancer Institute, and instructor of medicine at Harvard Medical School, discusses a new…
Daniel George, MD, questions whether debulking nephrectomy is still necessary in the age of targeted therapies. In a one-sided non-inferiority study, sunitinib alone was compared to nephrectomy. The…
This video includes information related to immunoglobulin therapy for primary immunodeficiencies. The AAAAI has developed 8 guiding principles for the effective use of IVIG for patients with primary…
In an interview during the 2020 OncLive® State of the Science Summit™ on Advanced Melanoma, Tracey Liebman, MD, assistant professor in the Ronald O. Perelman Department of Dermatology at the NYU…
Mikkael Sekeres, MD, director of the Leukemia Program and vice-chair for Clinical Research at the Cleveland Clinic Taussig Cancer Institute, discusses a phase 2 study of pevonedistat plus azacitidine…
Studies of pembrolizumab have shown promising antitumor activity across a wide cohort of patients with clear cell renal cell carcinoma (ccRCC). The results of a recent study, named…